CIM212930

CIM212930 is an orally bioavailable, small-molecule inhibitor of the sodium taurocholate co-transporting polypeptide (NTCP, SLC10A1). NTCP is a liver-specific transporter expressed on the basolateral membrane of hepatocytes that mediates the uptake of conjugated bile acids and serves as the entry receptor for the hepatitis B virus (HBV) and hepatitis delta virus (HDV). By blocking NTCP, CIM212930 inhibits viral entry of HBV and HDV and reduces hepatocellular bile acid accumulation. Developed by the Katholieke Universiteit Leuven (KU Leuven) and CISTIM, CIM212930 is being investigated for the treatment of chronic hepatitis B, hepatitis D, and cholestatic liver diseases. In preclinical models, it has demonstrated potent entry inhibition of HBV and HDV and has shown efficacy in reducing liver damage in cholestasis models.